Acam2000
Total Payments
$52,822
Transactions
5
Doctors
2
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $52,822 | 5 | 2 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $48,648 | 2 | 92.1% |
| Consulting Fee | $4,174 | 3 | 7.9% |
Payments by Type
Research
$48,648
2 transactions
General
$4,174
3 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Safety Surveillance Study of ACAM2000 Vaccinia Vaccine | Emergent BioSolutions Inc. | $48,648 | 0 |
Ad
Manufacturing Companies
- Emergent BioSolutions Inc. $52,822
Product Information
- Type Drug
- Total Payments $52,822
- Total Doctors 2
- Transactions 5
About Acam2000
Acam2000 is a drug associated with $52,822 in payments to 2 healthcare providers, recorded across 5 transactions in the CMS Open Payments database. The primary manufacturer is Emergent BioSolutions Inc..
Payment data is available from 2019 to 2019. In 2019, $52,822 was paid across 5 transactions to 2 doctors.
The most common payment nature for Acam2000 is "Unspecified" ($48,648, 92.1% of total).
Acam2000 is associated with 1 research study, including "Safety Surveillance Study of ACAM2000 Vaccinia Vaccine" ($48,648).